BioLineRx (NASDAQ:BLRX – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare BioLineRx to similar companies based on the strength of its institutional ownership, dividends, profitability, analyst recommendations, risk, earnings and valuation.
Analyst Ratings
This is a summary of current recommendations for BioLineRx and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
| BioLineRx Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 114.70%. Given BioLineRx’s rivals stronger consensus rating and higher probable upside, analysts clearly believe BioLineRx has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares BioLineRx and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioLineRx | $1.18 million | -$1.17 million | -0.57 |
| BioLineRx Competitors | $703.19 million | $8.65 million | -17.98 |
BioLineRx’s rivals have higher revenue and earnings than BioLineRx. BioLineRx is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares BioLineRx and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -502.08% | -34.80% | -18.27% |
| BioLineRx Competitors | -12,224.75% | -204.85% | -31.52% |
Risk & Volatility
BioLineRx has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Comparatively, BioLineRx’s rivals have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.
Insider & Institutional Ownership
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
BioLineRx rivals beat BioLineRx on 8 of the 13 factors compared.
About BioLineRx
BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
